Immunoscintigraphy of patients with head and neck carcinomas, with an anti‐angiogenetic antibody fragment

Abstract

These results may serve as a base for future therapeutical applications in human beings, with modified versions of the L19(scFv)2 antibody, designed to selectively deliver bioactive molecules into malignant tumors.